Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of “Buy” from Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIVGet Rating) has earned an average rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have covered the stock in the last year is $11.83.

Several brokerages recently commented on ROIV. Citigroup lifted their target price on shares of Roivant Sciences from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, January 5th. SVB Leerink lifted their target price on shares of Roivant Sciences from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Monday, December 19th. JPMorgan Chase & Co. began coverage on shares of Roivant Sciences in a report on Thursday, October 27th. They issued an “overweight” rating and a $7.00 target price on the stock. Finally, The Goldman Sachs Group lifted their target price on shares of Roivant Sciences from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Thursday, January 19th.

Insiders Place Their Bets

In related news, major shareholder Pharma Technologies Ltd Dexcel purchased 4,000,000 shares of the firm’s stock in a transaction on Thursday, November 10th. The shares were bought at an average cost of $5.00 per share, for a total transaction of $20,000,000.00. Following the transaction, the insider now directly owns 102,849,443 shares of the company’s stock, valued at approximately $514,247,215. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Financial Lp Qvt sold 5,656,081 shares of Roivant Sciences stock in a transaction dated Thursday, November 10th. The shares were sold at an average price of $4.75, for a total transaction of $26,866,384.75. Following the sale, the director now directly owns 5,470,181 shares in the company, valued at approximately $25,983,359.75. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Pharma Technologies Ltd Dexcel bought 4,000,000 shares of the firm’s stock in a transaction dated Thursday, November 10th. The shares were acquired at an average price of $5.00 per share, for a total transaction of $20,000,000.00. Following the completion of the transaction, the insider now owns 102,849,443 shares in the company, valued at approximately $514,247,215. The disclosure for this purchase can be found here. Insiders have sold 5,787,331 shares of company stock worth $27,840,207 in the last ninety days. Insiders own 13.00% of the company’s stock.

Institutional Trading of Roivant Sciences

Several institutional investors have recently made changes to their positions in ROIV. Bank of New York Mellon Corp boosted its position in shares of Roivant Sciences by 10.1% during the 1st quarter. Bank of New York Mellon Corp now owns 47,274 shares of the company’s stock valued at $233,000 after acquiring an additional 4,335 shares in the last quarter. Citigroup Inc. boosted its position in shares of Roivant Sciences by 1,803.6% during the 1st quarter. Citigroup Inc. now owns 5,749 shares of the company’s stock valued at $28,000 after acquiring an additional 5,447 shares in the last quarter. BlackRock Inc. boosted its position in shares of Roivant Sciences by 3.0% during the 1st quarter. BlackRock Inc. now owns 4,044,419 shares of the company’s stock valued at $19,980,000 after acquiring an additional 117,329 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Roivant Sciences by 13.8% during the 1st quarter. Vanguard Group Inc. now owns 1,319,499 shares of the company’s stock valued at $6,519,000 after acquiring an additional 159,787 shares in the last quarter. Finally, American International Group Inc. acquired a new stake in shares of Roivant Sciences during the 1st quarter valued at about $8,965,000. 52.66% of the stock is currently owned by institutional investors and hedge funds.

Roivant Sciences Stock Up 1.3 %

Roivant Sciences stock opened at $8.61 on Wednesday. The company has a market capitalization of $6.06 billion, a P/E ratio of -5.06 and a beta of 1.29. The firm’s fifty day simple moving average is $7.25 and its 200-day simple moving average is $5.23. The company has a current ratio of 7.43, a quick ratio of 7.43 and a debt-to-equity ratio of 0.25. Roivant Sciences has a 1-year low of $2.52 and a 1-year high of $10.00.

Roivant Sciences (NASDAQ:ROIVGet Rating) last released its quarterly earnings results on Monday, November 14th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). The business had revenue of $12.53 million for the quarter, compared to the consensus estimate of $6.71 million. Roivant Sciences had a negative net margin of 2,336.55% and a negative return on equity of 62.36%. Sell-side analysts forecast that Roivant Sciences will post -1.69 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

(Get Rating)

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.

Read More

Analyst Recommendations for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.